About Eun-mi Yu, MD
Dr. Angel Yu is a specialty oncology care physician board certified in medical oncology, hematology and internal medicine. She joined the Inova Health System in 2020 and has been in medical practice since 2012. Her area of interest is genitourinary cancers, which include prostate, bladder, kidney, and testicular cancers.
She completed her undergraduate education at the University of Pennsylvania with a major in biology, after which she received her doctorate in medicine at the Drexel University College of Medicine. She completed her internal medicine and hematology/oncology training at The George Washington University in Washington, DC.
Prior to joining Inova, Dr. Yu worked as a medical oncologist and hematologist with Novant Health and CaroMont Health, both based in North Carolina. She is excited to return to the DC area to focus on providing compassionate, personalized, and evidence-based oncology care to patients with genitourinary cancers.
- Alpha Omega Alpha Medical Honor Society – Inducted in 2009
- American Society of Clinical Oncology
Yu EM, Kittai A, Tabbara I. Chronic Lymphocytic Leukemia: Current Concepts. Anticancer Res. 2015 Oct;35(10):5149-65.
Kittai A, Yu EM, Tabbara I. Granulocytic sarcoma in a patient with chronic myeloid leukaemia in complete haematological, cytogenetic and molecular remission. BMJ Case Reports. 2014 Dec 23; doi:10.1136/bcr-2014-207466.
Yu EM, Kittai A, Aragon-Ching JB. Leiomyosarcoma: Risk Factors, Diagnosis and Treatment Options. 1st ed. New York: Nova Science Publishers; c2014. Chapter 2, Leiomyosarcomas of the Genitourinary Tract; p. 75-90.
El-Ayass W, Yu EM, Karcher DS, Aragon-Ching JB. Complete response to EPOCH in a patient with HIV and extracavitary primary effusion lymphoma involving the colon: a case report and review of literature. Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):144-7.
Yu EM, Jain M, Aragon-Ching JB. Angiogenesis inhibitors in prostate cancer therapy. Discov Med. 2010 Dec;10(55):521-30.
Yu EM, El-Ayass W, Aragon-Ching JB. The use of 5-alpha reductase inhibitors for the prevention of prostate cancer. Cancer Biol Ther. 2010 Jul 13;10(1).